FS Development Corp. II (NASDAQ:FSII) filed an 8-K this morning revealing that its shareholders have approved its combination with antiviral drug developer firm Pardes Biosciences.
Just 243,989 shares, or 1.2%, were redeemed in connection with the vote, removing roughly $2.4 million from its estimated trust of $201 million. FSII did have a minimum cash closing condition of $100 million and a sponsor support agreement in place of up to $25 million in the event there was less than $25 million in trust post-redemptions. However, clearly it was not needed in this case. This was a good result at a time when “good votes” are hard to come by.
FS II hit highs of $14.97 late last month as excitement stirred about the potential applications of Pardes’ oral antiviral drug candidate PBI-0451 for use in combatting COVID-19 infections. It has since settled down near its pro rata trust value of $10.
The parties initially announced their $657 million combination on June 29. California-based Pardes is developing two antiviral drug candidates and PBI-0451 has been fast-tracked through the FDA approval process.
All measures on FS II’s ballot passed by wide margins. For full vote tallies, click here.
ADVISORS
- Jefferies LLC and SVB Leerink acted as co-lead private placement agents for, and financial and capital markets advisor to, FS Development Corp. II.
- Goodwin Procter LLP acted as legal counsel to Pardes.
- White & Case LLP acted as legal counsel to FS Development Corp. II.
At the SPAC of Dawn With just weeks to go before the US presidential elections, SPACInsider will be examining many of the potential shifts in policy that could have implications for SPACs depending on the results. Another potential post-election shift could come at the SEC, where current Chairman Garry Gensler appears likely to stay on...
This week, the SPACInsider Podcast delves into some of the tax and accounting issues that SPAC teams should be considering as we approach both the Presidential election and the end of 2024. Mark Deters and Ryan Bixenman, partners at WithumSmith+Brown, join us to help break it all down. For example, what does it mean for...
At the SPAC of Dawn Trump Media (NASDAQ:DJT) is back on a tear, rising +18.5% in yesterday’s trading and a further +8% in the pre-market. This brings it above $32 for the first time since July and could reflect optimism about Donald Trump’s presidential bid, enthusiasm for the company’s new web-streaming Truth+ TV service (see...
At the SPAC of Dawn Today kicks off with an SEC holiday that may cool activity until Tuesday, but SPACs have still scheduled a pair of extension votes and completion votes this week, most of which are scheduled for tomorrow. Tuesday is also to play host to a vote for Investcorp India (NASDAQ:IVCA) shareholders to...
Terms Tracker for the Week Ending October 11, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week was sandwiched in between the Rosh Hashanah and Yom Kippur holidays, and as such, it was on the lighter side for news. In...